RecruitMe Clinical Trial

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Study of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis
Sponsor:Blueprint Medicines Corporation
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9514
U.S. Government ID:NCT03580655
Contact: Mark Heaney, MD: 646-317-5077 / mlh2192@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to test the safety and effectiveness of avapritinib (also known as BLU-285) in individuals who have been diagnosed with aggressive systemic mastocytosis (ASM), Systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell Leukemia (MCL). Avapritinib is an experimental drug means that is is not yet known if this drug will help patients. Open label means that you and your study doctor know you will receive avapritinib. This study will be conducted at multiple centers in the United States, Canada, Europe, and Australia.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a diagnosis of ASM, SM-AHN, or MCL?YesNo
Have you ever received treatment with avapritinib before?YesNo
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:

Mark Heaney, MD

mlh2192@cumc.columbia.edu

646-317-5077

YesYesNo3